Agenus Inc. Q1 2025 Update: Ligand Deal & Sales Agreements
Ticker: AGEN · Form: 10-Q · Filed: May 12, 2025 · CIK: 1098972
Sentiment: neutral
Topics: 10-Q, financial-reporting, agreements
TL;DR
AGENUS Q1 2025: Ligand deal closed, sales agreements active. Watch for updates.
AI Summary
Agenus Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing indicates various financial activities and agreements, including a Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated as of March 31, 2025. Agenus Inc. also references its "At Market Issuance Sales Agreement" dated August 8, 2024.
Why It Matters
This filing provides insight into Agenus Inc.'s ongoing business operations and financial arrangements, which could impact its future revenue and strategic partnerships.
Risk Assessment
Risk Level: medium — The filing details various agreements and financial instruments, suggesting potential complexities and market sensitivities.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of fiscal year 2025)
- 20250331 — Reporting Date (End date for the reported financial period)
Key Players & Entities
- AGENUS INC (company) — Filer
- Ligand Pharmaceuticals Incorporated (company) — Party to Purchase and Sale Agreement
- 20250331 (date) — End of Reporting Period
- 20240808 (date) — Date of At Market Issuance Sales Agreement
FAQ
What is the nature of the Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated?
The filing indicates a Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated as of March 31, 2025, but does not detail its specific terms or assets involved.
What are the key terms of the 'At Market Issuance Sales Agreement' dated August 8, 2024?
The filing mentions the 'At Market Issuance Sales Agreement' but does not provide specific details on its terms or the amount of securities that can be issued.
What was Agenus Inc.'s revenue for the first quarter of 2025?
The filing references 'agen:RevenueMember' for the period 2025-01-01 to 2025-03-31, but the specific revenue amount is not provided in the excerpt.
Does the filing provide details on Agenus Inc.'s intellectual property valuation?
The filing references 'us-gaap:IntellectualPropertyMember' and 'srt:MinimumMember' as of 2025-03-31, and 'us-gaap:TrademarksMember' with 'srt:MaximumMember' as of the same date, suggesting valuation considerations but not specific figures.
What is the significance of the 'SaponiQx Inc' mention in relation to the fiscal year 2024?
The filing lists 'agen:SaponiQxIncMember' in conjunction with the date '2024-12-31', implying a relationship or status relevant to the end of the 2024 fiscal year.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding AGENUS INC (AGEN).